Rockwell Medical Withdraws 2026 Financial Guidance on Expected Acquisition Costs

• Rockwell Medical withdrew its 2026 sales, profitability and operating cash flow guidance, citing expected transaction and financing expenses tied to its proposed acquisition.
• The combined business could generate annual revenue of $400 million to $450 million, subject to operating performance, exchange rates, market conditions and successful integration.
• The proposed acquisition of Vantive’s hemodialysis business carries a $125 million base price, with up to $45 million in additional milestone payments.
• Closing is expected in mid-2027, subject to regulatory approvals and other closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rockwell Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261102814598) on November 03, 2026, and is solely responsible for the information contained therein.